Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies

NCT04771572 is registered in ClinicalTrials.gov with Newave Pharmaceutical Inc as lead sponsor.

NCT NCT04771572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04771572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies
Lead sponsor
Newave Pharmaceutical Inc
Phase
Phase 1
Overall status
Recruiting
Start date
May 8, 2022
Completion date
December 31, 2027
Enrollment
100 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelomonocytic leukemia-2, multiple myeloma, myelodysplastic neoplasm in blast phase, myelodysplastic/myeloproliferative neoplasm, myelofibrosis, myeodysplastic syndrome, non hodgkin lymphoma, richter transformation, small lymphocytic lymphoma, t-cell-prolymphocytic leukemia